CALL US
+91 9891296838/9811747774

ONTRUZANT (trastuzumab-dttb) for injection, for intravenous use. Initial U.S. Approval: 2019. Available in India.

ONTRUZANT is a prescription medicine. ONTRUZANT is used to treat HER2-overexpressing breast cancer. Brand trastuzumab-dttb. Brand Name "ONTRUZANT (trastuzumab-dttb)" can be imported and made available on "Patient Name basis" treatment in India. If you have questions, please email IPN Support Team or Call Indian Pharma Network on +91 9891296838 (Mr. Tarun) / 9811747774 (Mr. Neeraj) for price list or cost in India.

ONTRUZANT is a prescription medicine. ONTRUZANT is used to treat HER2-overexpressing breast cancer.

Ontruzant is a HER2/neu receptor antagonist indicated for:
• The treatment of HER2-overexpressing breast cancer.
• The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product.


Source content : www.accessdata.fda.gov

ONTRUZANT (trastuzumab-dttb)injection suppliers for India and other countries. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of ONTRUZANT (trastuzumab-dttb)injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ONTRUZANT (trastuzumab-dttb)injection medicine cost price in India.

The order for ONTRUZANT (trastuzumab-dttb)injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Trastuzumab-dttb was first approved as a 150 mg single-dose vial by the FDA in January 2019 across all eligible indications, mainly adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease.

Trastuzumab-dttb is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer, including:
• As a part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel.
• With docetaxel and carboplatin.
• As a single agent following multi-modality anthracycline-based therapy.
In addition, trastuzumab-dttb is indicated in combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer and as a single agent for the treatment of HER2-overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease.

ONTRUZANT (trastuzumab-dttb) injection, for intravenous use.
Initial U.S. Approval: 2019

• For Injection: 150 mg lyophilized powder in a single-dose vial for reconstitution.
• For Injection: 420 mg lyophilized powder in a multiple-dose vial for reconstitution.
Please see the Full Prescribing Information, including Patient Information, for ONTRUZANT.
ONTRUZANT (trastuzumab-dttb)injection
You must agree before submitting.

News / Update for ONTRUZANT (trastuzumab-dttb).

For ONTRUZANT (trastuzumab-dttb) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

Merck Announces US Launch of ONTRUZANT ® (trastuzumab-dttb), a Biosimilar of Herceptin® (trastuzumab) For More Details

Samsung Bioepis Announces Four-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab-dttb) in Early or Locally Advanced HER2-positive Breast Cancer For More Details

Steps to access ONTRUZANT (trastuzumab-dttb) tablets.

Step 1. You send a request for your medicine online:- Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.

Step 2. We verify your prescription and medical details:- Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.

Step 3. We source your medicine:- Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 4. We deliver your medicine:- After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Documentation under Named-Patient import

Doctor’s Prescription –
We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

ONTRUZANT (trastuzumab-dttb)exporter and suppliers in India

Can I get anti-cancer medicines even if I am not based in India?
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find the best price of -
ONTRUZANT (trastuzumab-dttb)in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
ONTRUZANT (trastuzumab-dttb)in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
ONTRUZANT (trastuzumab-dttb)in North America – Mexico.
ONTRUZANT (trastuzumab-dttb)in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
ONTRUZANT (trastuzumab-dttb)in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
ONTRUZANT (trastuzumab-dttb)in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
ONTRUZANT (trastuzumab-dttb)in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
ONTRUZANT (trastuzumab-dttb)in Australia and New Zealand.

Room temperature shipping

For this medication, standard shipping applies. This means that a consistent room temperature of 15 to 25°C is maintained during transit.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines, used in HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer. Brand Name "ONTRUZANT (trastuzumab-dttb) for injection" or Generic Name "trastuzumab-dttb for injection" can be imported for personal use under "patient name basis" treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at urgent@indianpharmanetwork.co.in or call/WhatsApp at +91 9891296838 / 9811747774 to get access as per norms.